ADOCIA to Present New Data on AdoShell at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), today announced the latest preclinical data from its innovative AdoShell technology platform have been selected for presentations at four upcoming scientific conferences.

AdoShell Islets is an innovative immunoprotective hydrogel designed to encapsulate pancreatic islets, with the goal of curing diabetes through cell therapy without requiring immunosuppression. This semi-permeable hydrogel allows the diffusion of insulin and glucose, while preventing the infiltration of antibodies and immune cells that would lead to graft rejection. Currently, to prevent this normal body reaction, every allogeneic transplant patient must take immunosuppressive drugs on a chronic basis, with significant side effects. AdoShell is easily implantable and fully retrievable via laparoscopy.

The new data to be presented by Adocia notably disclose the success of the scale-up to deliver the therapeutic dose for the first-in-human study, which is planned to be submitted with the regulatory authorities in 2025.

In addition, new in vitro and in vivo data to be presented confirm the compatibility of AdoShell with stem cell-derived islets, notably their ability to mature into insulin producing cells within AdoShell. The integration of these stem cell-derived islets into our technology represents a key step toward broader access to type 1 diabetes treatment through cell therapy, without the need for immunosuppression.

Adocia envisions that AdoShell could be applied beyond pancreatic cells to other cell types. Data with primary and differentiated stem cells for the release of various therapeutic molecules other than insulin will also be presented, illustrating the possibility to make AdoShell a technology platform.

International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, New Orleans, USA, May 7-10, 2025

• AdoShell, a non-fibrotic encapsulation system for cell delivery
  • Session: Tissue Engineering; Embryonic, Organ and Other Tissue Specific Stem Cells
  • Presentation: Friday, May 9, 2025, 8:00 AM to 9:00 AM (CDT)
  • Ouardane Jouannot, Julie Brun, Romain Besnard, Clément Cocita, Alexandre Martin, Camille Gautier, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri, François Pattou, Olivier Soula

European Islet Study Group (EISG) 2025, Malmö, Sweden, June 11-13, 2025